Novel drug-delivery strategies for the treatment of ovarian cancer

References

• Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.21(17), 3194–3200 (2003).
   PubMed Web of Science ®Google Scholar
• du Bois A, Luck HJ, Meier W et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl Cancer Inst.95(17), 1320–1329 (2003).
   PubMed Web of Science ®Google Scholar
• Sandercock J, Parmar MK, Torri V, Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br. J. Cancer87(8), 815–824 (2002).
   PubMed Web of Science ®Google Scholar
• Miller ML, Ojima I. Chemistry and chemical biology of taxane anticancer agents. Chem. Rec.1(3), 195–211 (2001).
   PubMed Web of Science ®Google Scholar
• Sanderson BJ, Ferguson LR, Denny WA. Mutagenic and carcinogenic properties of platinum-based anticancer drugs. Mutat. Res.355(1–2), 59–70 (1996).
   PubMed Web of Science ®Google Scholar
• Friedrich M, Diesing D, Villena-Heinsen C et al. Taxanes in the first-line chemotherapy of metastatic breast cancer: review. Eur. J. Gynaecol. Oncol.25(1), 66–70 (2004).
   PubMed Web of Science ®Google Scholar
• Keresztes RS, Port JL, Pasmantier MW, Korst RJ, Altorki NK. Preoperative chemotherapy for esophageal cancer with paclitaxel and carboplatin: results of a Phase II trial. J. Thorac. Cardiovasc. Surg.126(5), 1603–1608 (2003).
   PubMed Web of Science ®Google Scholar
• Bajetta E, Del Vecchio M, Bernard-Marty C et al. Metastatic melanoma: chemotherapy. Semin. Oncol.29(5), 427–445 (2002).
   PubMed Web of Science ®Google Scholar
• Spencer CM, Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs48(5), 794–847 (1994).
   PubMed Web of Science ®Google Scholar
• Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs7(1), 78–86 (1996).
   PubMed Web of Science ®Google Scholar
• Weiss RB, Donehower RC, Wiernik PH et al. Hypersensitivity reactions from taxol. J. Clin. Oncol.8(7), 1263–1268 (1990).
   PubMed Web of Science ®Google Scholar
• Material Safety Data Sheets for carboplatin (2005).
   Google Scholar
• Markman M, Zanotti K, Webster K et al. Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum. Gynecol. Oncol.91(3), 573–576 (2003).
   PubMed Web of Science ®Google Scholar
• Tinker AV, Gebski V, Fitzharris B et al. Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel–ANZGOG 02–01. Gynecol. Oncol.104(3), 647–653 (2007).
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer4(6), 423–436 (2004).
   PubMed Web of Science ®Google Scholar
• O’Neill VJ, Kaye SB, Reed NS et al. A dose-finding study of carboplatin–epirubicin–docetaxel in advanced epithelial ovarian cancer. Br. J. Cancer86(9), 1385–1390 (2002).
   PubMed Web of Science ®Google Scholar
• Kerbusch T, Groenewegen G, Mathot RA et al. Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks. Br. J. Cancer90(12), 2268–2277 (2004).
   PubMed Web of Science ®Google Scholar
• Munoz R, Man S, Shaked Y et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT–cyclophosphamide metronomic chemotherapy. Cancer Res.66(7), 3386–3391 (2006).
   PubMed Web of Science ®Google Scholar
• Klement G, Huang P, Mayer B et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res.8(1), 221–232 (2002).
   PubMed Web of Science ®Google Scholar
• Man S, Bocci G, Francia G et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res.62(10), 2731–2735 (2002).
   PubMed Web of Science ®Google Scholar
• Kamat AA, Kim TJ, Landen CN Jr et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res.67(1), 281–288 (2007).
   PubMed Web of Science ®Google Scholar
• Krzyzanowska MK, Tannock IF, Lockwood G et al. A Phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother. Pharmacol. (2006).
   PubMed Web of Science ®Google Scholar
• Glode LM, Barqawi A, Crighton F, Crawford ED, Kerbel R. Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma. Cancer98(8), 1643–1648 (2003).
   PubMed Web of Science ®Google Scholar
• Almadrones LA. Treatment advances in ovarian cancer. Cancer Nurs.26(Suppl. 6), S16–S20 (2003).
   Google Scholar
• Vasey PA. Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br. J. Cancer89(Suppl. 3), S23–S28 (2003).
   Google Scholar
• Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol. Oncol.97(1), 10–15 (2005).
   PubMed Web of Science ®Google Scholar
• Armstrong DK, Bundy B, Wenzel L et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med.354(1), 34–43 (2006).
   PubMed Web of Science ®Google Scholar
• Miyagi Y, Fujiwara K, Kigawa J et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs intravenous infusion of carboplatin –a Sankai Gynecology Study Group (SGSG) study. Gynecol. Oncol.99(3), 591–596 (2005).
   PubMed Web of Science ®Google Scholar
• Kuhn WC. Therapy for recurrent ovarian cancer. Curr. Womens Health Rep.3(1), 33–38 (2003).
   PubMedGoogle Scholar
• Armstrong DK. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncologist7(Suppl. 5), 20–28 (2002).
   PubMed Web of Science ®Google Scholar
• Ferguson PJ. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. J. Otolaryngol.24(4), 242–252 (1995).
   PubMedGoogle Scholar
• Fraser M, Leung B, Jahani-Asl A et al. Chemoresistance in human ovarian cancer: the role of apoptotic regulators. Reprod. Biol. Endocrinol.1, 66 (2003).
   PubMedGoogle Scholar
• Ho EA, Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr. Cancer Drug Targets6(4), 295–311 (2006).
   PubMed Web of Science ®Google Scholar
• Lee ES, Na K, Bae YH. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J. Control. Release103(2), 405–418 (2005).
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Benoit JP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J. Control. Release112(2), 208–213 (2006).
   PubMed Web of Science ®Google Scholar
• Koziara JM, Whisman TR, Tseng MT, Mumper RJ. In-vivo efficacy of novel paclitaxel nanoparticles in paclitaxel-resistant human colorectal tumors. J. Control. Release112(3), 312–319 (2006).
   PubMed Web of Science ®Google Scholar
• Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist8(5), 411–424 (2003).
   PubMed Web of Science ®Google Scholar
• Marchetti P, Urien S, Cappellini GA, Ronzino G, Ficorella C. Weekly administration of paclitaxel: theoretical and clinical basis. Crit. Rev. Oncol. Hematol.44(Suppl.) S3–S13 (2002).
   Google Scholar
• Thomas H, Rosenberg P. Role of weekly paclitaxel in the treatment of advanced ovarian cancer. Crit. Rev. Oncol. Hematol.44(Suppl.) S43–S51 (2002).
   Google Scholar
• Hua J, Mutch DG, Herzog TJ. Stable suppression of MDR-1 gene using siRNA expression vector to reverse drug resistance in a human uterine sarcoma cell line. Gynecol. Oncol.98(1), 31–38 (2005).
   PubMed Web of Science ®Google Scholar
• Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat. Rev. Cancer3(7), 502–516 (2003).
   PubMed Web of Science ®Google Scholar
• Ho EA, Soo PL, Allen C, Piquette-Miller M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J. Control. Release117(1), 20–27 (2007).
   PubMed Web of Science ®Google Scholar
• Seidman AD, Hudis CA, Albanell J et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J. Clin. Oncol.16(10), 3353–3361 (1998).
   PubMed Web of Science ®Google Scholar
• Lau DH, Xue L, Young LJ, Burke PA, Cheung AT. Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother. Radiopharm.14(1), 31–36 (1999).
   PubMed Web of Science ®Google Scholar
• Sakuragi N, Nakajima A, Nomura E et al. Complications relating to intraperitoneal administration of cisplatin or carboplatin for ovarian carcinoma. Gynecol. Oncol.79(3), 420–423 (2000).
   PubMed Web of Science ®Google Scholar
• Hickey T, Kreutzer D, Burgess DJ, Moussy F. In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices. J. Biomed. Mater. Res.61(2), 180–187 (2002).
   PubMed Web of Science ®Google Scholar
• Fulzele SV, Satturwar PM, Dorle AK. Study of the biodegradation and in vivo biocompatibility of novel biomaterials. Eur. J. Pharm. Sci.20(1), 53–61 (2003).
   PubMed Web of Science ®Google Scholar
• Walter KA, Cahan MA, Gur A et al. Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res.54(8), 2207–2212 (1994).
   PubMed Web of Science ®Google Scholar
• Fung LK, Ewend MG, Sills A et al. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclo-phosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res.58(4), 672–684 (1998).
   PubMed Web of Science ®Google Scholar
• Shikanov A, Vaisman B, Krasko MY, Nyska A, Domb AJ. Poly(sebacic acid- co-ricinoleic acid) biodegradable carrier for paclitaxel: in vitro release and in vivo toxicity. J. Biomed. Mater. Res.69(1), 47–54 (2004).
   Web of Science ®Google Scholar
• Armstrong DK, Fleming GF, Markman M, Bailey HH. A Phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study. Gynecol. Oncol.103(2), 391–396 (2006).
   PubMed Web of Science ®Google Scholar
• Grant J, Blicker M, Piquette-Miller M, Allen C. Hybrid films from blends of chitosan and egg phosphatidylcholine for localized delivery of paclitaxel. J. Pharm. Sci.94(7), 1512–1527 (2005).
   PubMed Web of Science ®Google Scholar
• Ho EA, Vassileva V, Allen C, Piquette-Miller M. In vitro and in vivo characterization of a novel biocompatible polymer-lipid implant system for the sustained delivery of paclitaxel. J. Control. Release104(1), 181–191 (2005).
   PubMed Web of Science ®Google Scholar
• Guminska M, Ignacak J, Wojcik E. In vitro inhibitory effect of chitosan and its degradation products on energy metabolism in Ehrlich ascites tumour cells (EAT). Pol. J. Pharmacol.48(5), 495–501 (1996).
   PubMedGoogle Scholar
• Hasegawa M, Yagi K, Iwakawa S, Hirai M. Chitosan induces apoptosis via caspase-3 activation in bladder tumor cells. Jpn. J. Cancer Res.92(4), 459–466 (2001).
   PubMedGoogle Scholar
• Wang L, Khor E, Wee A, Lim LY. Chitosan–alginate PEC membrane as a wound dressing: assessment of incisional wound healing. J. Biomed. Mater. Res.63(5), 610–618 (2002).
   PubMed Web of Science ®Google Scholar
• Van de Vord PJ, Matthew HW, DeSilva SP et al. Evaluation of the biocompatibility of a chitosan scaffold in mice. J. Biomed. Mater. Res.59(3), 585–590 (2002).
   PubMed Web of Science ®Google Scholar
• Vassileva V, Grant J, De Souza R, Allen C, Piquette-Miller M. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model. Cancer Chemother. Pharmacol. (2007) (Epub ahead of print).
   PubMed Web of Science ®Google Scholar
• Liu J, Meisner D, Kwong E, Wu XY, Johnston MR. A novel trans-lymphatic drug delivery system: implantable gelatin sponge impregnated with PLGA–paclitaxel microspheres. Biomaterials28(21), 3236–3244 (2007).
   PubMed Web of Science ®Google Scholar
• Keskar V, Mohanty PS, Gemeinhart EJ, Gemeinhart RA. Cervical cancer treatment with a locally insertable controlled release delivery system. J. Control. Release115(3), 280–288 (2006).
   PubMed Web of Science ®Google Scholar
• Mikhailowski R, Shpitz B, Polak-Charcon S et al. Controlled release of TGF-β1 impedes rat colon carcinogenesis in vivo. Int. J. Cancer78(5), 618–623 (1998).
   PubMed Web of Science ®Google Scholar
• I-Plant™ Brachytherapy Seeds, prescribing information. Implant Sciences Corporation, MA, USA (2007).
   Google Scholar
• Gliadel® Wafer, prescribing information data sheet. MGI Pharma, MN, USA (2007).
   Google Scholar
• Viadur® prescribing information data sheet. Alza Corporation, CA, USA (2007).
   Google Scholar